RESUMEN
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruziquantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.
Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Enfermedad de Chagas/tratamiento farmacológico , Nitroimidazoles/farmacocinética , Tripanocidas/farmacocinética , Trypanosoma cruzi/efectos de los fármacos , Química Farmacéutica , Enfermedad de Chagas/metabolismo , Estudios de Seguimiento , Nitroimidazoles/administración & dosificación , Nitroimidazoles/sangre , Reacción en Cadena en Tiempo Real de la Polimerasa , Tripanocidas/administración & dosificación , Tripanocidas/sangre , Trypanosoma cruzi/aislamiento & purificaciónRESUMEN
Benznidazole (Bz) exhibits toxic side effects in animal studies and clinical use. Reductive metabolism of Bz in liver microsomes modulates the duration of its chemotherapeutic effect and its toxicity. The rate of this metabolism depends on age and is less intense in newborns and youngsters than in adults. In the present study, we determined Bz blood levels in rats of different ages that received Bz intragastrically (100 mg/kg). We developed and validated a high-pressure liquid chromatography with UV detector method for determination of Bz levels in whole blood. Bz levels were significantly higher and persisted for longer periods of time in the blood of young rats when compared to that of adult animals.
Asunto(s)
Animales , Ratas , Cromatografía Líquida de Alta Presión , Microsomas Hepáticos , Nitroimidazoles/sangre , Tripanocidas/sangre , Factores de Edad , Nitroimidazoles , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , TripanocidasRESUMEN
The aim of this study was to test the susceptibility of mice to Trypanosoma evansi treated with human plasma containing different concentrations of apolipoprotein L-1 (APOL1). For this experiment, a strain of T. evansi and human plasma (plasmas 1, 2, and 3) from 3 adult males clinically healthy were used. In vivo test used 50 mice divided in 5 groups (A to E) with 10 animals in each group. Animals of groups B to E were infected, and then treated with 0.2 ml of human plasma in the following outline: negative control (A), positive control (B), treatment with plasma 1 (C), treatment with plasma 2 (D), and treatment with plasma 3 (E). Mice treated with human plasma showed an increase in longevity of 40.9+/-0.3 (C), 20+/-9.0 (D) and 35.6+/-9.3 (E) days compared to the control group (B) which was 4.3+/-0.5 days. The number of surviving mice and free of the parasite (blood smear and PCR negative) at the end of the experiment was 90%, 0%, and 60% for groups C, D, and E, respectively. The quantification of APOL1 was performed due to the large difference in the treatments that differed in the source plasma. In plasmas 1, 2, and 3 was detected the concentration of 194, 99, and 115 mg/dl of APOL1, respectively. However, we believe that this difference in the treatment efficiency is related to the level of APOL1 in plasmas.